Home / MissionIR Articles / MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline

MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN) reported operational highlights and financial results for the third quarter ended Sept. 30, 2026, highlighting progress across its artificial intelligence (“AI”)-driven oncology pipeline and approximately $4 million in gross proceeds from financing completed at quarter end. In November, the company engaged its first clinical site to begin initial enrollment in a Phase 1b/2 trial targeting relapsed or refractory triple-negative breast cancer (“TNBC”). Lantern also received regulatory and institutional review board approvals in Taiwan in September to initiate Part 2 of its Phase 2 HARMONIC(TM) trial evaluating LP-300 in never-smokers with L858R-mutated non-small cell lung cancer.

The company additionally announced the November publication of peer-reviewed Phase 1a data for LP-184 in recurrent glioblastoma, supporting a planned Phase 1b/2a combination trial with spironolactone. Lantern’s clinical pipeline includes LP-300, LP-184 and LP-284, with development guided by its proprietary RADR(R) AI and machine learning platform to identify potential treatments across solid tumors, blood cancers and pediatric oncology.

To view the full press release, visit https://ibn.fm/0Pp3T

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN